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ABSTRACT
We recently reported that clofarabine, high-dose cytarabine, and granulocyte colony-stimulating factor (GCLAC) produced a 46% complete remission rate in relapsed/refractory acute myeloid leukemia.
GCLAC differs from FLAG by substitution of clofarabine for fludarabine, raising the question of the relative efficacy of these two regimens. We compared GCLAC given at the University of Washington Medical Center/Fred Hutchinson Cancer Research Center to fludarabine and cytarabine (FA) and FLAG given at MD Anderson Cancer Center. Independent multivariate analyses conducted at both institutions showed that after accounting for duration of first complete remission, salvage number, age, and cytogenetics, GCLAC was associated with a higher complete remission rate (odds ratio 9.57, p<0.0001) and longer survival (mortality hazard ratio 0.43, p=0.0002). Despite the retrospective nature of the analyses, GCLAC may be superior to FA/FLAG, particularly in patients with short duration of first complete remission or unfavorable cytogenetics.
The study was registered as NCT00602225 on ClinicalTrials.gov.
INTRODUCTION
We recently reported that clofarabine and high dose cytarabine preceded by G-CSF priming.
("GCLAC") produced a 46% complete remission rate in patients with relapsed or refractory acute myeloid leukemia (AML), although the relapsed patients had a median CR duration of only 6 months, with 36% of patients not having had a prior CR.
1 GCLAC was similar to the "FLAG" regimen (fludarabine, cytarabine (ara-C) and G-CSF priming), [2] [3] [4] [5] [6] [7] [8] [9] with clofarabine substituted for fludarabine.
Metabolism of both compounds to their triphosphates may increase synthesis of the triphosphate of ara-C (ara-CTP). 10, 11 However, clofarabine can also inhibit ribonucleotide reductase, 12, 13 resulting in fewer normally occurring deoxynucleotide triphosphates available to compete with ara-CTP for incorporation into DNA. Because the relative efficacies of GCLAC and fludarabine + ara-C + /-G-CSF remain uncertain, we performed a multivariate analysis comparing these salvage regimens.
DESIGN AND METHODS
Patient Selection
The GCLAC phase I/II protocol was approved by the Fred Hutchinson/University of Washington Cancer Consortium Institutional Review Board; all patients gave informed consent. Full details of the eligibility and patient characteristics are provided in the publication by Becker and colleagues.
1
Treatment with GCLAC
Patients began G-CSF, 5 mcg/kg daily by subcutaneous injection one day prior to chemotherapy, and received G-CSF daily until ANC rose to at least 2.0 for two consecutive days. Table I lists other pre-treatment characteristics of the GCLAC, FA, and FLAG cohorts. Forty percent of the GCLAC patients were refractory rather than relapsed, as compared to 25% of the FA patients, and 15% of the FLAG patients (p value not significant).
Statistical analysis
Comparison with fludarabine with (FLAG) or without (FA) G-CSF
Analyses of CR and survival were done independently at FHCRC and MDACC, with both centers using data from all patients given GCLAC or FA/FLAG. There were slight differences in the approaches, which we believe strengthen their independent conclusions. Criteria for CR and CRp were as typically specified. 14 Survival was calculated from the start of salvage therapy to death from any cause or to time of last follow up. Survival probabilities were estimated using the method of Kaplan and Meier and compared using the log-rank test. Differences in binary variables, including CR or CRp, were assessed with the Fisher exact test and differences in continuous variables with the Kruskal-Wallis test.
Multivariate analyses were used to inquire whether after accounting for relevant prognostic covariates treatment (GCLAC rather than FA/FLAG) affected CR or survival. Logistic regression was used for CR analyses and Cox regression for analyses of survival. The proportional hazard assumption was verified by the Grambsch-Therneau test. 15 Non-treatment covariates examined were those found to be associated, at p < 0.05, with CR or survival on univariate analyses. The covariates evaluated in the latter were: age, cytogenetics [with cytogenetic risk defined by Southwest Oncology Group criteria 16 ],duration of first CR, number of prior treatments for active AML, and at MDACC prior hematopoietic cell transplant (SCT) and year treated (1990-1994, 1995-1999,2000-2004,2005-2007, 2008-2010) . Terms were retained in the multivariate model if their p-value was < 0.05, and the same applied for terms describing interactions between treatment and covariates.
RESULTS AND DISCUSSION
To compare GCLAC with a similar regimen but with fludarabine replacing clofarabine, we used the MD Anderson Cancer Center salvage database. Because the database contained only 20 FLAG salvage patients, we also included the 81 patients who received FA salvage (FLAG without G-CSF);
previous MD Anderson data indicated that there was no difference between FA and FLAG in untreated patients (Estey et al, 1994) . CR rates were 22/81 with FA (27%; 95% CI 18-38%) and 4/20
with FLAG (20%, 6-44%) salvage (table 2) . Survival probabilities are shown in Figure 1 . The higher CR rate with GCLAC (46%) largely reflected results in patients with no initial CR ("primary refractory", 2/20 FA, 0/3 FLAG, 12/18 GCLAC) or with short (< 6 months) initial CR (2/19 FA, 0/5 FLAG, 4/12 GCLAC, Table 2 ). Response rates with GCLAC were also superior in patients with prognostically unfavorable cytogenetics ( Table 2, (Table 3 ). In particular, after accounting for the covariates illustrated in Table 3 each found that treatment with GCLAC was independently associated with a higher CR rate and longer survival. Multivariate analysis of CR rate demonstrated showed superior CR rate for GCLAC vs.
FA/FLAG with odds ratio 4.26, p=0.003 (MDACC) or odds ratio 9.57, p<0.0001 (FHCRC). For overall 6 survival, multivariate analysis at MDACC showed superiority for GCLAC (median 8.8 months) vs. FA (median 3.4 months, hazard ratio 0.39, p<0.0001) or vs. FLAG (median 3.8 months, hazard ratio 0.58, p=0.09). The multivariate analysis at FHCRC also showed longer survival for GCLAC vs.
FA/FLAG (hazard ratio 0.43, p=0.0002. Consistent with the observation that the principal benefit of GCLAC was in patients with no or a brief CR1 (Table 2) , multivariate analysis also indicated that there was an interaction between CR1 duration and treatment with GCLAC (p =0.02)
The activity of clofarabine + ara-C as salvage therapy for AML has been previously described, 17 but questions regarding its efficacy relative to other regimens have arisen. Here we use multivariate analyses, done independently at MDACC and FHCRC, to demonstrate that GCLAC is at least as good and plausibly superior to regimens using the same dose and schedule of ara-C but employing fludarabine rather than clofarabine. Furthermore the analyses found that response to GCLAC was less dependent on 1 st CR duration than was the case with FA or FLAG.
Several potentially confounding factors deserve mention. First, a higher proportion of patients who were "primary refractory" prior to receiving GCLAC as opposed to FA or FLAG had not received an initial induction regimen containing ara-C at a dose of ≥1.5g/m The utilization of salvage regimens as a bridge to transplant may lead to higher survival rates for more effective regimens. For the GCLAC study, half of the patients were able to proceed to allogeneic stem cell transplant.
In summary, a multivariate analysis shows that the GCLAC regimen exhibited higher overall efficacy than fludarabine/cytarabine combinations, and a randomized comparison between GCLAC and other salvage regimens is warranted.
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